BACKGROUND: Radical prostatectomy (RP) has limited cancer control potential for the patient with high-risk prostate cancer (Pca). We prospectively examined the efficacy and safety of neoadjuvant therapy with luteinizing hormone-releasing hormone (LHRH) agonist þ low-dose estramustine phosphate (EMP) (LHRH þ EMP) followed by RP. METHODS: High-risk Pca was defined by the D'Amico stratification system. A total of 142 patients with high-risk Pca were enrolled in this trial from September 2005 to March 2011. The LHRH þ EMP therapy included administration of LHRH agonist and 280 mg day --1 EMP for 6 months before RP. Pathological cancer-free (pT0) rate on the surgical specimen was the primary end point. Secondary end points were PSA-free survival and toxicity. RESULTS: The average patient age was 67.4 years (interquartile range (IQR) 72, 65) and the median initial PSA level was 14.80 ng ml --1 (IQR 26.22, 7.13). The median Gleason score was 9 (IQR 9, 7) and 97 patients (68.3%) had clinical stage T2c or T3. All patients completed 6 months of LHRH þ EMP neoadjuvant therapy with no delays in RP. Seven patients (4.9%) achieved pT0. Surgical margins were negative in 125 patients (87.0%). At a median follow-up period of 34.9 months, PSA-free survival was 84.3%. No serious adverse events were reported during the study and there were no toxicityrelated deaths. CONCLUSIONS: Six months of LHRH þ EMP neoadjuvant therapy followed by RP is safe and oncological outcomes are acceptable. Although this study was a single-arm trial with a relatively short follow-up, this treatment may have a potential to improve PSA-free survival in high-risk Pca patients. Further clinical trials are warranted.
INTRODUCTION
According to the D'Amico risk stratification, patients who have PSA levels of 20 ng ml --1 or greater, Gleason scores of 8 or higher, or clinical stage T2c/T3 are defined as high-risk localized or locally advanced prostate cancer (Pca). 1 In this group of patients, reported rates of PSA-free survival after local therapy range from 30 to 50%. 1, 2 Neoadjuvant hormonal therapy alone before radical prostatectomy (RP) reduces the rate of positive surgical margins and can achieve a pathological complete response. However, neoadjuvant androgen deprivation therapy has shown no benefits in patient outcomes, especially PSA-free survival, in randomized trials. 3--6 Several studies have reported similar results with neoadjuvant docetaxel in high-risk Pca patients. 7--10 Although various trials try to achieve pT0 or prolonged PSA-free survival, the pT0 rate was ranged from 0 to 2.8% 9--11 and the PSA-free survival rate was still low. 8, 12 We thought that other combination with hormonal and cytotoxic agents may contribute to improve oncological outcome of high-risk Pca. Estramustine phosphate (EMP) is a compound of estrogen and nitrogen mustard, which deregulates microtubule assembly. 13, 14 We have reported the active effect of luteinizing hormone-releasing hormone (LHRH) plus EMP for the patients with advanced Pca. 15, 16 We expected that this combination may be applicable to neoadjuvant therapy for the patients with high-risk Pca.
In this prospective study, we assessed the activity and safety of neoadjuvant LHRH plus low-dose EMP (LHRH þ EMP) before RP in patients with high-risk Pca.
MATERIALS AND METHODS

Study population
This was a prospective single-arm study carried out at a teaching hospital in Japan. All enrolled patients were Japanese. High-risk Pca was defined as clinical stage T2c or T3, and/or initial PSA levels of 20 ng ml --1 or greater, and/ or a biopsy Gleason sum score of 8 or higher according to the D'Amico risk stratification system. 1 Eligible patients had histologically confirmed high-risk Pca without lymph node or distant metastasis, an Eastern Cooperative Oncology Group (ECOG) performance status of 0--1, adequate bone marrow function (absolute neutrophil count X1500 m --3 and platelet count X100 000 m --3
), adequate renal function (creatinine o2.0 mg dl --1 and/or creatinine clearance 440 ml min --1 ), and adequate hepatic function (total bilirubin o1.5 mg dl --1 ). Patients who underwent prior radiation therapy for the prostate or pelvis, or had received chemotherapy or hormonal therapy for Pca were not enrolled. The patients who administered finasteride or dutasteride before surgery were excluded in this study.
The present neoadjuvant therapy achieved 4.6% of pT0 at our preliminary study. 17 The highest pT0 rate ever reported was 2.8%. 9 Therefore, we expected the highest pT0 rate for the neoadjuvant therapy as around 5% in this study. All patients were informed about the treatment protocol, and provided written consent. The study protocol and informed consent documents were reviewed and approved by the Hirosaki University institutional review board.
Treatment
All treatments in this study were undertaken at our institution. All patients received LHRH agonist (leuprolide 11.25 mg or goserelin acetate 10.8 mg every 3 months) and EMP 280 mg day --1 for 6 months before RP. The use of our retropubic retrograde technique with RP was previously described in detail. 18 All patients in this study underwent the same lymphadenectomy procedure, which included removal of the bilateral obturator lymph node chains.
Patient evaluation
Baseline evaluation included complete history and physical examination, assessment of ECOG performance status, serum testosterone and PSA levels, abdominal and pelvic computed tomography or magnetic resonance imaging, and chest X-ray or computed tomography.
Toxicity was evaluated after neoadjuvant LHRH þ EMP every 3 months and graded by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.
Prostatectomy specimens were evaluated by a single pathologist at our institution according to International Society of Urological Pathology 2005. 19 The apex of the prostate was shaved perpendicular to the prostatic urethra. The bladder neck margin was coned from the specimen and sectioned perpendicularly. The remaining prostate was completely sectioned at 3 mm intervals in a plane perpendicular to the urethral axis. All tumors were staged by the 2002 American Joint Committee on Cancer staging manual. 20 Absence of evidence of cancer in the prostate and lymph node specimens was classified as a pT0.
Follow-up schedule
Following surgery, all patients were assessed by measuring serum PSA and testosterone at 3-month intervals. The date of disease recurrence or PSA failure was defined as when the serum PSA level exceeded 0.2 ng ml --1 . If PSA did not decrease to o0.2 ng ml --1 after surgery, the date of RP was defined as date of disease recurrence.
Statistical analysis
Data were analyzed using SPSS 18.0 statistical software (SPSS, Chicago, IL, USA). PSA-free survival was analyzed by the Kaplan--Meier method. The relationship between survival and subgroup classification was analyzed using the log-rank test. All P-values were two-sided, and the significance level was set at Po0.05. The primary end point was the percentage of patients showing pT0. The secondary end points were PSA-free survival and toxicity.
RESULTS
Patient characteristics
From September 2005 to March 2011, 142 patients with high-risk Pca were enrolled. The pre-treatment characteristics of these patients are listed in Table 1 . The mean patient age was 67.4 years (interquartile range (IQR) 72, 65). All patients received neoadjuvant LHRH þ EMP according to the aforementioned protocol.
Surgical outcomes All patients completed neoadjuvant therapy and underwent RP. Deep vein thrombosis or pulmonary embolism was not seen in our series. The median operative time for RP including bilateral lymphadenectomy was 110 min (IQR 129, 94) and median estimated blood loss was 853 ml (IQR 1285, 610). The median number of removed lymph nodes was 8 (IQR 12, 4).
We experienced one rectal injury (0.7%) with intraoperative complication, which was successfully repaired. Leakage from the vesicourethral anastomosis, which is the most frequent perioperative complication, occurred in 26 patients (18.3%), and surgical site infection occurred in 3 (2.1%).
Change in serum testosterone level Chronological change in serum testosterone levels ± s.d. was shown in Figure 1 . The median serum testosterone level was 442 ± 133 ng ml --1 (IQR 516, 375) at baseline. Serum testosterone level had decreased to castration levels in all patients within 3 months after starting neoadjuvant therapy and maintained o50 ng ml --1 until RP. Serum testosterone level became o20 ng ml --1 in 107 patients (75.3%). The nadir serum testosterone level was 10 ± 10 ng ml --1 (IQR 15, 5) at the time of operation. The median serum testosterone levels 3 and 6 months after surgery were 225±78 and 338±125 ng ml --1 , respectively.
Pathological outcomes
The estimated preoperative prostate volume on transrectal ultrasonography was 29.1 ml (IQR 37.9, 22.3). The median surgical Figure 1 . Change in serum testosterone levels. The median serum testosterone level was 442 ng ml --1 at baseline. The nadir serum testosterone level was 10 ng ml --1 (interquartile range 15, 5) at the time of operation. The median serum testosterone levels 3 and 6 months after surgery were 225 and 338 ng ml --1 , respectively. (Figure 2) . The 3-year PSA-free survival rate was 96.9% for patients in clinical stage T1c to T2b (95% CI, 33.5--36.6) and 78.5% for patients in clinical stage T2c or greater (95% CI, 53.2--63.9; P ¼ 0.035) (Figure 3a) .
The 3-year PSA-free survival rate was 91.5% in patients who achieved pathological T0 to T2 status (95% CI, 60.1--67.4) and 68.9% in those with T3 status (95% CI, 42.8--60.0; P ¼ 0.001) (Figure 3b) . The 3-year PSA-free survival rate was 86.9% in patients with negative surgical margins (95% CI, 61.2--69.1) and 53.0% in those with positive surgical margins (95% CI, 23.3--45.7; Po0.0001) (Figure 3c ).
Safety of neoadjuvant LHRH plus EMP
No serious adverse events were reported during the study and there were no toxicity-related deaths. No grade 3 or 4 toxicities occurred ( Table 2 ). The most common LHRH þ EMP-related adverse event was grade 1 gynecomastia (98.6%). All adverse events occurred within 3 months after administration of LHRH þ EMP.
DISCUSSION
According to previous literatures, pT0 rate have been reported to range from 0 to 2.8%.
9--11 To achieve better oncologic outcome of high-risk Pca is one of the major concerns in urological oncology. 21 The results with phase II studies using docetaxel-based neoadjuvant therapy have been indicated that pathological cancer-free status and acceptable PSA-free survival can rarely be achieved although gefitinib was added on Figure 2 . Kaplan--Meier estimate of PSA-free survival. At 34.5 months, the PSA-free survival rate was 86.0%. docetaxel. 22 Neoadjuvant ketoconazole and docetaxel chemotherapy has been reported to achieve 36% of PSA-free survival, 23 which showed no remarkable improvement compared with the previous literatures.
1,2 Furthermore, majority of the reported clinical trials in neoadjuvant setting were small-sized with relatively short follow-up. Most recently, at 2012 ASCO annual meeting, Taplin et al. 24 reported that neoadjuvant LHRH plus abiraterone acetate therapy achieved high pT0 rate (10%). The biochemical outcome was not presented, however, this regimen may be a promising for the treatment of high-risk Pca.
The advantages of EMP as compared with other cytotoxic drugs are its estrogenic effects 25 as well as its ease of oral administration and relatively good tolerability at the effective dose. However, in our preliminary study, a number of patients experienced gastrointestinal adverse effects at regular dose with 560 mg day --1 . 17 Therefore, we reduced the dose of EMP to 280 mg day --1 for continuous administration for 6 months.
An LHRH agonist administration desensitizes the pituitary and reduces testicular function. However, switching of an LHRH agonist to other LHRH agonist in castration-resistant Pca patients achieved further decrease in PSA levels. 26 This event suggests that LHRH agonists may have other important functions such as directly effect on testicular tissue function. 26 Furthermore, several studies have shown that LHRH agonist treatment directly inhibits the proliferation of both androgen-sensitive and androgen-insensitive Pca with no relation to androgen levels. 27--29 EMP decreases serum testosterone to castration level, 25 however, there is an advantage to use EMP in combination with LHRH agonist. In fact some authors reported the superiority of combination of EMP and LHRH agonist to orchiectomy alone or androgen deprivation therapy for the patients with advanced Pca. 15, 16, 30 In this study, 4.9% of patients achieved pT0, which can be acceptable antitumor effect. No serious adverse events occurred and there were no toxicity-related deaths. All patients completed the protocol therapy and underwent RP without delay. We experienced 1 (0.7%) rectal injury, leakage from the vesicourethral anastomosis in 26 patients (18.3%) and surgical site infection occurred in 3 (2.1%), which are acceptable as complications involved in RP for patients with high-risk Pca.
The long-term administration of low-dose EMP may have positive impact on the relatively long PSA-free survival of 84.3%, which corresponds to that in low-or intermediate-risk patients who treated RP alone in our clinic. 18 However, our study has some limitations including study design and participant population. This study is a single-arm trial performed at a single institution in Japan. The mean follow-up period of 34.9 months is not long enough and all participants were Japanese. Several authors have indicated the racial differences in response and adverse effect of hormonal therapy in PCa. 31, 32 These issues should be addressed in the future. Neoadjuvant therapy for high-risk prostate cancer T Koie et al
